226 related articles for article (PubMed ID: 31212367)
1. Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
Yu W; Li J; Wang Q; Wang B; Zhang L; Liu Y; Tang M; Xu G; Yang Z; Wang X; Zhang J; Liu Y; Shi G
Prostate; 2019 Aug; 79(11):1304-1315. PubMed ID: 31212367
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference.
Fu YK; Wang BJ; Tseng JC; Huang SH; Lin CY; Kuo YY; Hour TC; Chuu CP
J Biomed Sci; 2022 Feb; 29(1):16. PubMed ID: 35197069
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
4. POH1 Knockdown Induces Cancer Cell Apoptosis via p53 and Bim.
Wang CH; Lu SX; Liu LL; Li Y; Yang X; He YF; Chen SL; Cai SH; Wang H; Yun JP
Neoplasia; 2018 May; 20(5):411-424. PubMed ID: 29573636
[TBL] [Abstract][Full Text] [Related]
5. POH1 contributes to hyperactivation of TGF-β signaling and facilitates hepatocellular carcinoma metastasis through deubiquitinating TGF-β receptors and caveolin-1.
Wang B; Xu X; Yang Z; Zhang L; Liu Y; Ma A; Xu G; Tang M; Jing T; Wu L; Liu Y
EBioMedicine; 2019 Mar; 41():320-332. PubMed ID: 30745168
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
Sakai I; Miyake H; Terakawa T; Fujisawa M
Cancer Sci; 2011 Apr; 102(4):769-75. PubMed ID: 21214673
[TBL] [Abstract][Full Text] [Related]
9. Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G
Lee E; Decker AM; Cackowski FC; Kana LA; Yumoto K; Jung Y; Wang J; Buttitta L; Morgan TM; Taichman RS
J Cell Biochem; 2016 Dec; 117(12):2815-2824. PubMed ID: 27153245
[TBL] [Abstract][Full Text] [Related]
10. The JAMM motif of human deubiquitinase Poh1 is essential for cell viability.
Gallery M; Blank JL; Lin Y; Gutierrez JA; Pulido JC; Rappoli D; Badola S; Rolfe M; Macbeth KJ
Mol Cancer Ther; 2007 Jan; 6(1):262-8. PubMed ID: 17237285
[TBL] [Abstract][Full Text] [Related]
11. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
Zeng J; Liu W; Fan YZ; He DL; Li L
Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
[No Abstract] [Full Text] [Related]
12. Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo.
Yu F; Lin Y; Xu X; Liu W; Tang D; Zhou X; Wang G; Zheng Y; Xie A
Int J Oncol; 2020 Jul; 57(1):139-150. PubMed ID: 32319597
[TBL] [Abstract][Full Text] [Related]
13. Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression.
Ahmed AA; Robinson T; Palande M; Escara-Wilke J; Dai J; Keller ET
J Cell Biochem; 2019 Oct; 120(10):16946-16955. PubMed ID: 31099068
[TBL] [Abstract][Full Text] [Related]
14. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
16. Proteasome-associated deubiquitinase ubiquitin-specific protease 14 regulates prostate cancer proliferation by deubiquitinating and stabilizing androgen receptor.
Liao Y; Liu N; Hua X; Cai J; Xia X; Wang X; Huang H; Liu J
Cell Death Dis; 2017 Feb; 8(2):e2585. PubMed ID: 28151478
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
18. Deficiency of NEIL3 Enhances the Chemotherapy Resistance of Prostate Cancer.
Wang Y; Xu L; Shi S; Wu S; Meng R; Chen H; Jiang Z
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921035
[TBL] [Abstract][Full Text] [Related]
19. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
20. Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration.
Obinata D; Takada S; Takayama K; Urano T; Ito A; Ashikari D; Fujiwara K; Yamada Y; Murata T; Kumagai J; Fujimura T; Ikeda K; Horie-Inoue K; Homma Y; Takahashi S; Inoue S
Eur J Cancer; 2016 Apr; 57():39-49. PubMed ID: 26854828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
